amphotericin-b and Plasmacytoma

Topics: Amphotericin B; Bradycardia; Daunorubicin; Female; Humans; Kidney Neoplasms; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Plasmacytoma

The ability of amphotericin B (AmB) to potentiate the cytotoxicity of several different anticancer agents against two murine tumor models was examined. A spleen colony assay was used to quantitate the cytotoxicity of BCNU, CCNU, and L-PAM, either alone or in combination with AmB against the MOPC-315 plasmacytoma. A high level of potentiation of the effects of CCNU and L-PAM by AmB occurred, but AmB did not increase the cytotoxicity of BCNU. Tumor growth curves and calculation of cell survival demonstrated significant potentiation of the cytotoxicity of CCNU by AmB against SC Lewis lung carcinoma.

Topics: Amphotericin B; Animals; Antineoplastic Agents; Drug Synergism; Drug Therapy, Combination; Female; Lomustine; Lung Neoplasms; Male; Mice; Mice, Inbred Strains; Plasmacytoma

Two tumor systems were used to test prophylactic effects of amphotericin B (AmB). When 0.5 mg AmB was given ip every 2 weeks to AKR mice beginning at 8 weeks of age, the 50% tumor incidence for spontaneous lymphoma development was delayed 2-3 months. In the second tumor system, BALB/c mice received injections of either 20 or 50 mug AmB before receiving MOPC-315-C cells sc. The mice given the low dose of AmB demonstrated a decreased tumor incidence and a reduced tumor growth rate, when compared with controls. Opposite effects were found for the group administered the high dose; tumor incidence and rate of growth were increased.

Topics: Adjuvants, Immunologic; Amphotericin B; Animals; Dose-Response Relationship, Drug; Leukemia, Experimental; Mice; Mice, Inbred AKR; Mice, Inbred BALB C; Neoplasms, Experimental; Plasmacytoma